Posted by Michael Wonder on 10 Nov 2020
Lilly's neutralising antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorisation for the treatment of recently diagnosed COVID-19
9 November 2020 - Bamlanivimab is authorised for treatment of recently diagnosed, mild to moderate COVID-19 in high-risk patients.
The U.S. FDA today granted emergency use authorisation for Eli Lilly and Company's investigational neutralising antibody bamlanivimab (LY-CoV555) 700 mg.
Bamlanivimab is authorised for the treatment of mild to moderate COVID-19 in adults and paediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalisation.
